Second infusion of designer cells aims to rescue failing hearts

NCT ID NCT07516288

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early study tests whether a second infusion of a patient's own modified immune cells (CAR-DC) is safe and can improve heart function in 5 adults with end-stage dilated cardiomyopathy. Participants had already received one dose but saw their heart function worsen again. The goal is to see if a repeat dose can help control the disease without serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY (DCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dilated cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DILATED CARDIOMYOPATHY (DCM) HEART FAILURE

Contacts and locations

Locations

Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang / 浙江, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.